Cerebricon Limited, Kuopio, Finland.
J Alzheimers Dis. 2011;27(3):499-510. doi: 10.3233/JAD-2011-110881.
The purpose of this study was to evaluate the efficacy of the radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) in alleviating behavioral deficits and reducing amyloid-β (Aβ) accumulation in an Alzheimer's disease (AD) transgenic Tg2576 mouse model. Daily treatment with IAC (3-30 mg/kg, i.p.) was started at the age of 6 months and continued until the mice were 13 months old. At the age of 9 months and again at 12 months, the mice were tested in open field and water maze tests. At the age of 13 months, the mice were sacrificed and the brains processed for immunohistochemistry. Mortality was significantly reduced in all IAC-treated groups. In addition, IAC treatment improved the water maze hidden platform training performance but had no effect on motor activity in the open field or water maze swim speed in transgenic mice. Lastly, IAC treatment (10 mg/kg) significantly reduced the cortical Aβ plaque burden. In vitro, IAC is able to increase the number of neurites and neurite branches in cultured cortical primary neurons. In conclusion, IAC slowed down the development of the AD-like phenotype in Tg2576 mice and accelerated neurite growth in cultured neurons.
本研究旨在评估自由基清除剂 IAC(双(1-羟基-2,2,6,6-四甲基-4-哌啶基)癸二酸盐)在缓解行为缺陷和减少阿尔茨海默病(AD)转基因 Tg2576 小鼠模型中淀粉样蛋白-β(Aβ)积累方面的疗效。IAC(3-30mg/kg,腹腔注射)的每日治疗从 6 个月大开始,持续到 13 个月大。在 9 个月大和 12 个月大时,对小鼠进行了旷场和水迷宫测试。在 13 个月大时,对小鼠进行安乐死并进行免疫组织化学处理。所有 IAC 治疗组的死亡率均显著降低。此外,IAC 治疗改善了水迷宫隐藏平台训练表现,但对转基因小鼠的旷场或水迷宫游泳速度的运动活动没有影响。最后,IAC 治疗(10mg/kg)显著降低了皮质 Aβ斑块负担。体外,IAC 能够增加培养的皮质原代神经元中的神经突和神经突分支的数量。总之,IAC 减缓了 Tg2576 小鼠中类似 AD 的表型的发展,并加速了培养神经元中的神经突生长。